Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Alexandre, Duvignaud"'
Autor:
Romain Blaizot, Gregoire Pasquier, Abdoulaye Kassoum Kone, Alexandre Duvignaud, Magalie Demar
Publikováno v:
Parasites & Vectors, Vol 17, Iss 1, Pp 1-18 (2024)
Abstract Background Cutaneous leishmaniasis (CL) is understudied in sub-Saharan Africa. The epidemiology of CL is determined by the species involved in its transmission. Our objectives were to systematically review available data on the species of Le
Externí odkaz:
https://doaj.org/article/2b01680e2a1d411780f6e1c5dbfc82e2
Autor:
Geoffrey Garcia, Sylvie Labrouche-Colomer, Alexandre Duvignaud, Etienne Clequin, Charles Dussiau, David-Alexandre Trégouët, Denis Malvy, Renaud Prevel, Atika Zouine, Isabelle Pellegrin, Julien Goret, Maria Mamani-Matsuda, Antoine Dewitte, Chloe James
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-18 (2024)
Abstract Background Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive.
Externí odkaz:
https://doaj.org/article/9b57d2df4cc14bfab42efddcb511b951
Autor:
Carine Grenier, Macha Loniewski, Mélanie Plazy, Racha Onaisi, Marie-Hélène Doucet, Jean-Philippe Joseph, Alexandre Duvignaud, Denis Malvy, Xavier Anglaret, Joanna Orne-Gliemann, the Coverage study group
Publikováno v:
Archives of Public Health, Vol 80, Iss 1, Pp 1-10 (2022)
Abstract Background The emergency set-up and implementation of outpatient clinical trials on epidemic emerging infectious diseases such as COVID-19 raise many issues in terms of research structuration, regulations, and health systems organization. We
Externí odkaz:
https://doaj.org/article/450c10513c634982800b538120e215d5
Autor:
Oussama Mouri, Cléa Melenotte, Romain Guéry, Camille Cotteret, Arnaud Schweitzer-Chaput, Alice Perignon, Marc Thellier, Emmanuelle Bourrat, Florentia Kaguelidou, Jean Yves Siriez, Denis Malvy, Jean-Pierre Gangneux, Alexandre Duvignaud, Christophe Ravel, Salvatore Cisternino, Janet Ransom, Eric Caumes, Olivier Lortholary, Max Grogl, Pierre Buffet
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 17, Iss 8, p e0011492 (2023)
BackgroundIn endemic foci, the use of an aquaphilic cream containing paromomycin with/without gentamicin to treat cutaneous leishmaniasis (CL) is safe, painless and cures 78-82% of patients with New and Old World CL. Self-application in travelers req
Externí odkaz:
https://doaj.org/article/088c64dac03348fc8fad665a2632743c
Autor:
Jenny L. Schnyder, Federico Gobbi, Mirjam Schunk, Andreas Lindner, Fernando Salvador, Alexandre Duvignaud, Marta Arsuaga Vicente, Jean Claude Dejon Agobé, Paolo Cattaneo, Giulia Bertoli, Camilla Rothe, Mia Wintel, Diana Pou, Denis Malvy, Ayola Akim Adegnika, Hanna K. De Jong, Martin P. Grobusch
Publikováno v:
New Microbes and New Infections, Vol 53, Iss , Pp 101136- (2023)
Background: Earlier studies found characteristic haematological changes in African patients with active schistosomiasis. If consistently present, full blood counts (FBC) may be helpful to diagnose schistosomiasis also in migrants and returning travel
Externí odkaz:
https://doaj.org/article/36f75a9cd0404ce494b11f96ba07edb9
Autor:
Laure Burguet, Alexandre Duvignaud, Duc Nguyen, Marie-Catherine Receveur, Hannah Kaminski, Isabelle Pellegrin, Anne-Marie Rogues, Olivia Peuchant, Karine Moreau, Pierre Merville, Lionel Couzi
Publikováno v:
International Journal of Infectious Diseases, Vol 117, Iss , Pp 251-257 (2022)
Objectives: To describe the investigation, follow-up, management, and outcomes in a cohort of chronic kidney disease (CKD) and kidney transplant recipients (KTR) exposed to a case of pulmonary tuberculosis (TB). Methods: Contacts were investigated fo
Externí odkaz:
https://doaj.org/article/6c3d6bcdce654ab7be286b529ee4baa5
Autor:
Sonali R. Gnanenthiran, Claudio Borghi, Dylan Burger, Bruno Caramelli, Fadi Charchar, Julio A. Chirinos, Jordana B. Cohen, Antoine Cremer, Gian Luca Di Tanna, Alexandre Duvignaud, Daniel Freilich, D. H. Frank Gommans, Abraham E. Gracia‐Ramos, Thomas A. Murray, Facundo Pelorosso, Neil R. Poulter, Michael A. Puskarich, Konstantinos D. Rizas, Rodolfo Rothlin, Markus P. Schlaich, Michael Schreinlecher, Ulrike Muscha Steckelings, Abhinav Sharma, George S. Stergiou, Christopher J. Tignanelli, Maciej Tomaszewski, Thomas Unger, Roland R. J. van Kimmenade, Richard D. Wainford, Bryan Williams, Anthony Rodgers, Aletta E. Schutte
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 17 (2022)
Background Published randomized controlled trials are underpowered for binary clinical end points to assess the safety and efficacy of renin‐angiotensin system inhibitors (RASi) in adults with COVID‐19. We therefore performed a meta‐analysis to
Externí odkaz:
https://doaj.org/article/1f10e3a056824f04b0479f27b6c3925f
Autor:
Alex P Salam, Alexandre Duvignaud, Marie Jaspard, Denis Malvy, Miles Carroll, Joel Tarning, Piero L Olliaro, Peter W Horby
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 16, Iss 3, p e0010289 (2022)
Ribavirin is currently the standard of care for treating Lassa fever. However, the human clinical trial data supporting its use suffer from several serious flaws that render the results and conclusions unreliable. We performed a systematic review of
Externí odkaz:
https://doaj.org/article/0035a81957e54460bac1f44288f08a61
Autor:
Alexandre Duvignaud, Edouard Lhomme, Thierry Pistone, Racha Onaisi, Rémi Sitta, Valérie Journot, Duc Nguyen, Nathan Peiffer-Smadja, Antoine Crémer, Stéphane Bouchet, Thomas Darnaud, Delphine Poitrenaud, Lionel Piroth, Christine Binquet, Jean-François Michel, Benjamin Lefèvre, David Lebeaux, Josselin Lebel, Julie Dupouy, Caroline Roussillon, Anne Gimbert, Linda Wittkop, Rodolphe Thiébaut, Joanna Orne-Gliemann, Jean-Philippe Joseph, Laura Richert, Xavier Anglaret, Denis Malvy, the COVERAGE study group
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-3 (2020)
Abstract Objectives To assess the efficacy of several repurposed drugs to prevent hospitalisation or death in patients aged 65 or more with recent symptomatic SARS-CoV-2 infection (COVID-19) and no criteria for hospitalisation. Trial design Phase III
Externí odkaz:
https://doaj.org/article/f09c7f006a924356be2d7eab55c2380e
Publikováno v:
EBioMedicine, Vol 67, Iss , Pp 103342- (2021)
Externí odkaz:
https://doaj.org/article/86e4ffcea98d4e838f77660a7771133a